

Patients may or may not meet eligibility requirements as established by Alberta Government sponsored drug programs.

PATIENT INFORMATION

PATIENT LAST NAME	FIRST NAME	INITIAL	COVERAGE TYPE <input type="checkbox"/> Alberta Blue Cross <input type="checkbox"/> Alberta Human Services <input type="checkbox"/> Other
DATE OF BIRTH: Year / Month / Day	ALBERTA PERSONAL HEALTH NUMBER		
STREET ADDRESS	CITY	PROV	POSTAL CODE
			IDENTIFICATION/CLIENT/COVERAGE No:

SPECIALIST IN RESPIROLOGY OR CLINICAL IMMUNOLOGIST INFORMATION

PRESCRIBER LAST NAME	FIRST NAME	INITIAL	PRESCRIBER PROFESSIONAL ASSOCIATION REGISTRATION	
STREET ADDRESS			<input type="checkbox"/> CPSA	<input type="checkbox"/> ACO
			<input type="checkbox"/> CARNA	<input type="checkbox"/> ADA+C
CITY, PROVINCE			<input type="checkbox"/> ACP	<input type="checkbox"/> Other
POSTAL CODE			PHONE:	FAX:
FAX NUMBER MUST BE PROVIDED WITH EACH REQUEST SUBMITTED				

Please provide the following information for ALL requests:

Diagnosis: <input type="checkbox"/> Severe Asthma → a) Most recent date of confirmation of diagnosis : _____ b) Has the patient been under your care > 1 year? <input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> Other (specify): _____	Current weight (kg): _____	<input type="checkbox"/> Smoker <input type="checkbox"/> Non-Smoker
--	----------------------------	--

Provide the following pre-treatment information for NEW requests for treatment naive and treatment experienced patients:

Total serum human immunoglobulin (IgE) (IU/ml)	Date	AQLQ – Juniper Score	Date
<input type="checkbox"/> Confirmation of IgE mediated allergy to a perennial allergen by clinical history and allergy skin testing	Date	Score #1	Date
FEV1 (pre-bronchodilator % predicted)	Date	Score #2	Date

Number of exacerbations of asthma within the previous 12 month period prior to starting omalizumab that resulted in:

An Emergency Room visit / Hospitalization: _____ Unscheduled physician visits resulting in oral corticosteroids: _____

Please check one of the following :

- One or more severe exacerbations of asthma requiring a hospital admission or Emergency Room visit within the previous year while on systemic corticosteroids; **OR**
- One or more severe exacerbations of asthma requiring a hospital admission or Emergency Room visit requiring documented use of systemic corticosteroids (oral corticosteroids initiated or increased for at least 3 days, or parenteral corticosteroids); **OR**
- Three or more severe exacerbations of asthma within the previous year, which required an unscheduled physician visit and resulted in courses (or chronic use >50% of the year) of systemic corticosteroids.

Previous medications utilized: Name of Medication, dose, duration and response is required for **ALL** of the following:

- High-dose inhaled corticosteroids :
- Long-acting beta-2 agonists :
- Oral corticosteroids :

Chronic use (>50% of the year) of oral corticosteroids? YES NO

Provide the following information for all RENEWAL requests and for INITIAL requests for treatment experienced patients:

Current FEV1 (pre-bronchodilator % predicted)	Date	Current AQLQ – Juniper Score	Date
		Current ACQ-5 Score	Date

Number of exacerbations of asthma within the previous 12 month period while on omalizumab that resulted in:

An Emergency Room visit / Hospitalization: _____ Unscheduled physician visits resulting in oral corticosteroids: _____

Please check ALL of the following that apply :

- Patient demonstrated at least a 25% reduction in the number of exacerbations, which required oral corticosteroids from the 12 months prior to initiation of omalizumab that required systemic corticosteroids.
- For patients that were on chronic (>50% of the year) courses of oral corticosteroids use in the prior 12 months to initiation of omalizumab, tapering of oral corticosteroid use by at least 25% from baseline.
- A reduction in the number of exacerbations that have led to a hospital admission or emergency room visits, compared to the 12 months prior to the commencement of omalizumab.

PRESCRIBER'S SIGNATURE	DATE	Please forward this request to: • Alberta Blue Cross, Clinical Drug Services 10009-108 Street NW, Edmonton, Alberta T5J 3C5 • FAX: 780-498-8384 in Edmonton • 1-877-828-4106 toll free all other areas
------------------------	------	---

ONCE YOUR REQUEST HAS SUCCESSFULLY TRANSMITTED, PLEASE DO NOT MAIL OR RE-FAX YOUR REQUEST.